🔗 Share this article

Given that the US continues making unprecedented changes to its vaccine schedules, one figure appears somewhat surprisingly: Høeg, a US-based physician and epidemiologist who first made her name by casting doubt on COVID-19 shots in the global health crisis and has concentrated on alleged deaths after Covid immunization in her recent time at the Food and Drug Administration.

Planned Shifts to Childhood Immunization Program

Health officials planned to announce major changes to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s immunization schedule, sources say – a substantial departure that would put the US out of step with many the world with no evidence for public health gain. The planned update has been pushed back until the next year.

Rather than the director of the vaccine center, Dr. Høeg is listed to present at the meeting. She was recently named acting director of the FDA’s CDER, the fifth individual to head the office this year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a closer partnership between the drug and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a greater focus upon dismantling long-standing immunizations at the FDA.

Høeg has often pushed for halting specific childhood immunization guidelines in the US so as to align more like Denmark, a country with comprehensive healthcare and a number of inhabitants about the size of the state of Wisconsin.

So far statements, she has continued to focus on vaccination policy – usually the responsibility of Prasad, director of the FDA’s CBER – instead of medication approval.

Questions Over Background

Høeg has no obvious track record in pharmaceutical research, oversight or administrative roles, which has been standard for past heads of the biologics center. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for leading the CDER, said Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a major agency. She is not an expert in drug approvals.”

Past commissioners of the center would “be deeply familiar with legal statutes and the research of pharmaceutical innovation”, noted a former acting FDA commissioner. “Frankly, she has not acquired the sort of resume that former directors who led the center have had.”

The drug center has an vast workload at the FDA, Woodcock emphasized.

“The public just focuses on the innovative therapies, but the generic program approves numerous generic medications. There is also a biosimilars division, OTC medication office and so forth, and every single one must be managed,” Dr. Woodcock explained. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a significant leadership aspect to the role, which supervises in excess of 5,000 employees. “It is a massive management job, if you execute it properly,” the former official concluded.

Response and Contentious Policies

In response to inquiries about Høeg’s credentials and whether this selection represents increased cooperation among regulatory chiefs on vaccines, a press secretary said that the “concerns stem from flawed assumptions”.

“Her resume is consistent with the functions of her role,” the official explained, noting the months Høeg spent counseling the agency head on “drug safety and regulatory science, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg takes over the commissioner’s controversial expedited review system, a controversial one-day therapy clearance system that allegedly troubled her former heads. “By what process are these therapies being chosen for this expedited pathway? Who is making the decisions?” Howard asked. “There is a lot of confidentiality going on at the agency right now.”

Broadly speaking, he stated, “the agency looks to be trending towards less stringent regulations of all drugs, except for shots.”

Documented Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if troubling, track record, some experts observe. She released a study using non-validated public submissions to estimate the frequency of myocarditis following Covid immunization. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccinations are pose a greater threat than they are.

Among her “wish list” for the new federal leadership encompassed revising rules for novel immunizations and halting “unnecessary” vaccines, she said after the election on a audio program. At the FDA, Dr. Høeg has according to sources proposed barring young men from receiving Covid vaccines.

“She’s an complete true believer who starts off with her conclusions and tailors the evidence to retrofit the science in a extremely deceptive, dishonest way,” Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg became part of other contrarians, {like|